OncoMatch/Clinical Trials/NCT07153796
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Is NCT07153796 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Blinatumomab and Mini-CVD for b-cell acute lymphoblastic leukemia.
Treatment: Blinatumomab · Mini-CVD · MTX/ARA-C — This is a single arm open-label phase 2 trial to study the safety and efficacy of SC Blinatumomab in combination with low-intensity chemotherapy for older or unfit patients with B-ALL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Excluded: ABL1 fusion
Philadelphia positive (+) B-ALL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: SC Blinatumomab (blinatumomab)
Prior history of therapy with SC Blinatumomab
Cannot have received: investigational therapy
No other investigational therapy within the past 14 days
Lab requirements
Kidney function
estimated creatinine clearance of > 50 mg/min/1.73m2
Liver function
bilirubin less than or equal to 3.5 mg, ALT and/or AST less than or equal to 5 times institutional upper limit of normal
Cardiac function
Patients with a cardiac ejection fraction as measured by MUGA or TTE <40% [excluded]
Adequate organ function with estimated creatinine clearance of > 50 mg/min/1.73m2, bilirubin less than or equal to 3.5 mg, ALT and/or AST less than or equal to 5 times institutional upper limit of normal. Patients with a cardiac ejection fraction as measured by MUGA or TTE <40% [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify